By Leonard Kamugisha Akida
ENTEBBE
Cabinet has approved the appointment of Dr Christine Kirunga Tashobya as chairperson of the seven-member board of directors of the National Drug and Health Products Authority (NDHPA).
ICT and National Guidance Minister Justine Kasule Lumumba announced the appointments while briefing the media on Cabinet resolutions at the Uganda Media Centre in Kampala on Tuesday.
The minister said appointments were approved during a Cabinet meeting chaired by President Yoweri Museveni at State House, Entebbe.
These will serve a four-year term, renewable once, Lumumba said.
Tashobya holds a PhD and master’s degree in Public Health, a master’s degree in Health Policy, Planning and Financing, and another in Demography. She also holds a bachelor’s degree in Medicine and Surgery and has 35 years of experience in public health and health systems governance. She is also the Vice Chairperson of the Team University Council.
Other members appointed to the board are Dr Jerome Mpaata Owagage representing the Pharmaceutical Society of Uganda and expertise in health law; Engineer Tadeo Byabagambi representing biomedical engineering and medical devices; and Margaret Naleoga, with expertise in financial management and forensic investigations.
Others are Katherine Adok, a lawyer and human rights activist; Dr Francis Omajor, representing natural chemotherapeutics and traditional medicine; and Nassur Gaddafi, representing young people, with experience in public policy, consumer interests and community representation.
“These will serve a four-year term, renewable once,” Lumumba said.
The NDHPA is a new regulatory body established to oversee medicines and other health products in Uganda, established under the National Drug and Health Products Authority Act, 2026 (Act 5 of 2026). President Museveni assented to the law on April 27, 2026. It repeals the National Drug Policy and Authority Act of 1993 and expands the regulatory mandate to cover pharmaceuticals, medical equipment, diagnostics, public health chemicals and cosmetics.
As a body corporate, the authority has a separate legal identity, enabling it to own property, enter into contracts, and sue or be sued in its own name.
The new law broadens the scope of regulation beyond the previous framework, which primarily focused on medicines and related products.



































